Company intelligence / Profile preview
Hope Biosciences
- Ownership
- Private
- Development stage
- Phase 2
Overview
As of 2023, Hope Biosciences cultured approximately 170 billion adult stem cells for use in dozens of disease and injury conditions, including in 18 FDA-authorized research protocols. Their autologous adipose derived mesenchymal stem cells (HB-adMSCs) were authorized for use in a rare form of pediatric drug-resistant epilepsy.
- Therapeutic areas
- RheumatologyEndocrinologyImmunologyOncologyNeurologyInfectious Diseases
- Modalities
- Mesenchymal stem cells (MSCs)Adult stem cell therapeuticsAutologous adipose derived mesenchymal stem cells (HB-adMSCs)
- Industry
- Biotech
Drug pipeline
8 assets7 more assets in the full pipeline.
Request access →Partnerships
Beyond the preview
Go deeper on Hope Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hope Biosciences.